Skip to main content

LCD L37725: MolDX: Melanoma Risk Stratification Molecular Testing

LCD L37725, MolDX: Melanoma Risk Stratification Molecular Testing, is the Local Coverage Determination that Palmetto GBA applies to claims from 7 states (AL, GA, NC, SC, TN, VA, WV), effective 2025-06-26 and first in force 2018-12-03. The policy text runs 184 words, and its billing and coding article A56961 lists 24 ICD-10-CM codes that support medical necessity for 4 procedure codes. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 24 covered ICD-10-CM codes: the same total as L37750 (Noridian Healthcare Solutions, LLC, 24 codes, revised 2026-01-22) and the same total as L38016 (CGS Administrators, LLC, 24 codes, revised 2025-06-26).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Palmetto GBA
States and territories
7
AL GA NC SC TN VA WV
Revision effective
2025-06-26
Original effective
2018-12-03
Policy text
184 words
Covered ICD-10 codes (articles)
24

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L37725
ContractContractorTypeStates
11201Palmetto GBAA and B and HHH MACSC
11301Palmetto GBAA and B and HHH MACVA
11401Palmetto GBAA and B and HHH MACWV
11501Palmetto GBAA and B and HHH MACNC
11202Palmetto GBAA and B and HHH MACSC
11302Palmetto GBAA and B and HHH MACVA
11402Palmetto GBAA and B and HHH MACWV
11502Palmetto GBAA and B and HHH MACNC
10111Palmetto GBAA and B MACAL
10211Palmetto GBAA and B MACGA
10311Palmetto GBAA and B MACTN
10112Palmetto GBAA and B MACAL
10212Palmetto GBAA and B MACGA
10312Palmetto GBAA and B MACTN

Billing and coding article A56961: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56961 (Billing and Coding: MolDX: Melanoma Risk Stratification Molecular Testing) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A56961: Billing and Coding: MolDX: Melanoma Risk Stratification Molecular Testing (Billing and Coding, effective 2025-10-01)

Covered ICD-10-CM codes
24
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
4
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A56961
ICD-10-CMDescription (FY2027)
C43.0Malignant melanoma of lip
C43.10Malignant melanoma of unspecified eyelid, including canthus
C43.111Malignant melanoma of right upper eyelid, including canthus
C43.112Malignant melanoma of right lower eyelid, including canthus
C43.121Malignant melanoma of left upper eyelid, including canthus
C43.122Malignant melanoma of left lower eyelid, including canthus
C43.20Malignant melanoma of unspecified ear and external auricular canal
C43.21Malignant melanoma of right ear and external auricular canal
C43.22Malignant melanoma of left ear and external auricular canal
C43.30Malignant melanoma of unspecified part of face
C43.31Malignant melanoma of nose
C43.39Malignant melanoma of other parts of face
C43.4Malignant melanoma of scalp and neck
C43.51Malignant melanoma of anal skin
C43.52Malignant melanoma of skin of breast
C43.59Malignant melanoma of other part of trunk
C43.60Malignant melanoma of unspecified upper limb, including shoulder
C43.61Malignant melanoma of right upper limb, including shoulder
C43.62Malignant melanoma of left upper limb, including shoulder
C43.70Malignant melanoma of unspecified lower limb, including hip
C43.71Malignant melanoma of right lower limb, including hip
C43.72Malignant melanoma of left lower limb, including hip
C43.8Malignant melanoma of overlapping sites of skin
C43.9Malignant melanoma of skin, unspecified

Procedure codes: 0578U, 81479, 81529, 81599.

Coverage indications, limitations and medical necessity

Molecular diagnostic tests used to assist in risk stratification of melanoma patients are covered when ALL of the following are true:

• The patient has a personal history of melanoma AND:

• Either:

• Has Stage T1b and above OR

• Has T1a with documented concern about adequacy of microstaging

• Is undergoing workup or being evaluated for treatment, AND

• Does not have metastatic disease AND

• Presumed risk for a positive Sentinel Lymph Node Biopsy (SLNB) based on clinical, histological, or other information is >5% AND

• Has a disease stage, grade, and Breslow thickness (or other qualifying conditions) within the intended use of the test

• The TEST has demonstrated, as part of a Technical Assessment:

• Clinical validity of analytes tested in predicting metastatic disease (or the absence of metastatic disease) in peer-reviewed scientific literature

• Utility beyond clinical, histological, and radiographical factors in the ability to accurately stratify patients into risk groups to manage patient care, such by precluding unnecessary sentinel lymph node biopsies

• Appropriate analytical validity

• Performance characteristics equivalent or superior to other covered, similar tests

Summary of evidence (opening)

Cutaneous melanoma (CM) is increasing in incidence in the U.S., with an estimated 96,480 cases expected to be diagnosed in 2019 with 7,230 deaths. 1

In the treatment of CM, the risk that a patient has or will develop metastatic disease is central to many of the decision management choices in cutaneous melanoma, with more aggressive management or treatment strategies recommended for patients who are at a higher risk. 2 Per current national guidelines, a SLNB procedure is considered for all patients with melanoma pathologic Stage T1b and above, as well as those patients with T1a tumors in whom there is significant uncertainty about the adequacy of microstaging. 2,3 Patients with a positive SLN are at substantially increased risk for distant metastatic disease and death; 4 however, the procedure only provides prognostic information, and the MSLT-II study showed no survival benefit associated with completion lymphadenectomy in SLN positive patients. 5 Currently, the identification of SLN positive patients helps identify Stage III patients who can potentially benefit from targeted and immunotherapeutic agents in the adjuvant setting. 6-8 The procedure can be associated with complications in a substantial proportion of patients such as pain, seromas, nerve damage and edema, and requires a large team of dedicated personnel, including nuclear medicine physicians, surgeons, and pathologists. 9-11 It has been estimated that the cost of a SLNB can be 10 times that of a wide excision alone, and the cost per life saved in a patient population with low prevalence of positive SLN can approach 1 million dollars. 12 Overall, the likelihood of a positive SLN after the SLNB procedure is 16%, 4,13 but this is variable for specific populations. 13-16 Elderly patients account for a substantial proportion of CM patients, and 60% of melanoma-related deaths occur in patients ≥65 years-old. While older age is associated with a poor prognosis, fewer elderly patients are SLN positive, 14-18 which indicates that the prognostic value of SLNB is limited in this population. 19,20 In general, a 5% likelihood for a positive SLN is recommended as a threshold for performing this procedure in a patient population. 13

Molecular diagnostic tests have been proposed to help managing clinicians risk stratify patients for selecting their most appropriate management based on their probability of developing metastatic disease; these tests may score patients’ probabilities of resultant metastatic disease by measuring tumor biomarkers such as relevant gene expression. 21-24 One gene expression profile (GEP) test (DecisionDx Melanoma, Castle Biosciences) was evaluated in a retrospective cohort (n=782) to evaluate its ability to predict metastasis and ability to predict SLNB status with tumors with a Breslow thickness 25

The ability of the test to identify a low-risk group was initially assessed and compared to SLNB in 2 contemporary, multi-center, prospective study cohorts: a 584 patient cohort from 2 published prospective studies (overall 14% SLN positive rate) 23,26 and a 837 patient cohort from prospectively tested patients at 5 large academic institutions (overall 12% SLN positive rate). 25 The rate of SLN positivity in both prospective study cohorts aligns with the SLN positivity rate in the general population of melanoma patients who have undergone SLNB. The results show that in patients from the Medicare-eligible population (65 years old and over) who were determined to be low-risk by this test, the concordance of a negative SLNB was 98.4%. These studies showed improved performance in other patient groups as well.

The contractor cites 49 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2018-12-03
Current revision effective
2025-06-26
Last reviewed by the contractor
2025-05-07
MCD version
44

Other related documents: A59070 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L37725 cover?

Molecular diagnostic tests used to assist in risk stratification of melanoma patients are covered when ALL of the following are true: The full 184-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L37725 apply to?

Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L37725?

The companion billing and coding article A56961 lists 24 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L37725?

A denial under LCD L37725 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56961's 24 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.